TropIQ’s parasitology platform drove the optimisation of pantothenamide compounds that generated MMV’183: a candidate for further clinical development with a new mode of action for treatment of malaria and blocking transmission. The results of the research that led to the discovery of this molecule are now published by Nature Communications.